US · EUDA · MEDICAL - CARE FACILITIES
EUDA Health Holdings Limited (EUDA) intrinsic value and stock valuation
$15.96as of 2026-11-21 · Mkt cap 32.15M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
EUDA Health Holdings Limited DCF and intrinsic value
InvestorsCraft values EUDA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from EUDA’s statements →
EUDA Health Holdings Limited Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2020–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.82M | $4.01M | $3.71M | $3.76M | $4.56M |
| Operating income | -$-2.44M | -$-17.34M | -$-3.96M | -$-5.72M | -$-560K |
| Net income | -$-2.77M | -$-15.36M | -$-10.04M | -$-24.88M | $860K |
| EPSd | -$-1.49M | -$-9.48M | -$-8.73M | -$-41.47M | $1.87M |
| Operating cash flow | -$-2.43M | -$-2.03M | -$-2.92M | -$-1.53M | $440K |
| Capital expenditure | -$-100K | -$-120K | -$0.00 | -$-20K | -$0.00 |
| Free cash flow | -$-2.53M | -$-2.15M | -$-2.92M | -$-1.54M | $440K |
| Total assets | $1.72M | $1.73M | $1.31M | $25.6M | $8M |
| Total debt | $2.4M | $1.27M | $3.37M | $3.63M | $460K |
| Net debt | $2.06M | $1.03M | $3.19M | $3.57M | $270K |
| Total equity | -$-4.27M | -$-2.57M | -$-7.48M | -$-3.51M | $600K |
| Cash and short-term investments | $350K | $240K | $190K | $60K | $190K |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.82M | $4.01M | $3.71M | $3.76M | $4.56M |
| Cost of revenue | $3.83M | $3.25M | $2.86M | $2.89M | $3.31M |
| Gross profit | $2.99M | $760K | $840K | $870K | $1.25M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $20K | $130K |
| Selling, general and administrative expenses | $5.43M | $3.34M | $4.8M | $6.75M | $1.81M |
| Other expenses | $0.00 | $14.8M | $0.00 | $6.32M | -$-130K |
| Operating expenses | $5.43M | $18.1M | $4.8M | $13.1M | $1.81M |
| Cost and expenses | $9.26M | $21.4M | $7.67M | $16M | $5.12M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $1.92M |
| Interest expense | $230K | $40K | $20K | $90K | $130K |
| Depreciation and amortization | $410K | $170K | $110K | $260K | $260K |
| Ebitda | -$-2.09M | -$-17.42M | -$-8.3M | -$-24.56M | $1.34M |
| Operating income | -$-2.44M | -$-17.34M | -$-3.96M | -$-5.72M | -$-560K |
| Total other income/expenses, net | -$-290K | -$-310K | -$-4.47M | -$-19.21M | $2.23M |
| Income before tax | -$-2.73M | -$-17.64M | -$-8.43M | -$-24.93M | $1.67M |
| Income tax expense | $40K | -$0.00 | $0.00 | -$-20K | $50K |
| Net income | -$-2.77M | -$-15.36M | -$-10.04M | -$-24.88M | $860K |
| Weighted average shares outstanding | $1.86M | $1.62M | $1.36M | $600K | $460K |
| Weighted average diluted shares outstanding | $1.86M | $1.62M | $1.15M | $600K | $460K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $350K | $240K | $190K | $60K | $190K |
| Net receivables | $330K | $170K | $240K | $190K | $4.09M |
| Inventory | $0.00 | $130K | $0.00 | $650K | $0.00 |
| Total current assets | $1.04M | $760K | $720K | $25M | $4.35M |
| Property, plant and equipment, net | $330K | $320K | $210K | $120K | $160K |
| Goodwill and intangible assets | $160K | $340K | $0.00 | $0.00 | $1.28M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $2.2M |
| Total non-current assets | $680K | $970K | $590K | $600K | $3.65M |
| Total assets | $1.72M | $1.73M | $1.31M | $25.6M | $8M |
| Accounts payable | $10K | $30K | $0.00 | $1.46M | $2.82M |
| Short-term debt | $2.33M | $1.22M | $3.3M | $3.62M | $430K |
| Deferred revenue | $520K | $480K | $0.00 | -$-3.69M | $0.00 |
| Total current liabilities | $5.84M | $4.14M | $8.72M | $29.1M | $7.32M |
| Long-term debt | $70K | $50K | $80K | $20K | $30K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $150K | $160K | $80K | $20K | $80K |
| Capital lease obligations | $200K | $230K | $200K | $60K | $110K |
| Total liabilities | $5.98M | $4.3M | $8.79M | $29.1M | $7.4M |
| Common stock | $48.8M | $47.8M | $27.4M | $21.3M | $330K |
| Retained earnings | -$-52.87M | -$-50.1M | -$-34.74M | -$-24.7M | $180K |
| Accumulated other comprehensive income (loss) | -$-210K | -$-260K | -$-190K | -$-130K | $10K |
| Total equity | -$-4.27M | -$-2.57M | -$-7.48M | -$-3.51M | $600K |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $2.2M |
| Total debt | $2.4M | $1.27M | $3.37M | $3.63M | $460K |
| Net debt | $2.06M | $1.03M | $3.19M | $3.57M | $270K |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-2.77M | -$-17.6M | -$-8.44M | -$-24.95M | $900K |
| Depreciation and amortization | $410K | $170K | $120K | $170K | $260K |
| Stock-based compensation | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-230K | $190K | $530K | $1.12M | $1.18M |
| Accounts receivable | -$-170K | $80K | -$-30K | -$-170K | -$-260K |
| Inventory | $50K | -$-130K | $0.00 | $3.69M | $0.00 |
| Accounts payable | -$-10K | $20K | $0.00 | -$-1.13M | $1.38M |
| Net cash provided by operating activities | -$-2.43M | -$-2.03M | -$-2.92M | -$-1.53M | $440K |
| Investments in property, plant and equipment | -$-80K | -$-120K | -$0.00 | -$-20K | -$0.00 |
| Acquisitions, net | $0.00 | $20K | $0.00 | -$0.00 | -$-350K |
| Net cash used for investing activities | -$-100K | -$-150K | $0.00 | -$-270K | -$-360K |
| Common stock issued | $100K | $50K | $790K | $1.1M | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $2.55M | $2.32M | $2.35M | $2.49M | -$-170K |
| Net change in cash | $110K | $40K | -$-590K | $590K | -$-60K |
| Cash at end of period | $350K | $240K | $200K | $780K | $190K |
| Operating cash flow | -$-2.43M | -$-2.03M | -$-2.92M | -$-1.53M | $440K |
| Capital expenditure | -$-100K | -$-120K | -$0.00 | -$-20K | -$0.00 |
| Free cash flow | -$-2.53M | -$-2.15M | -$-2.92M | -$-1.54M | $440K |
Line items
Line items
Line items
About EUDA Health Holdings Limited
EUDA Health Limited, established in 2019, is a Singapore-based enterprise dedicated to advancing digital healthcare. It provides an innovative platform facilitating online medical consultations for routine, non-urgent health concerns. This entity functions as a subsidiary of Watermark Developments Limited.
- CEO
- Alfred Lim
- Employees
- 123
- Beta
- 0.68
Explore
Frequently asked questions
What is the intrinsic value of EUDA Health Holdings Limited (EUDA)?
EUDA Health Holdings Limited (EUDA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is EUDA undervalued?
EUDA trades at a price of $15.96 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.